Your browser is no longer supported. Please, upgrade your browser.
MYL Mylan N.V. daily Stock Chart
MYL [NASD]
Mylan N.V.
IndexS&P 500 P/E144.46 EPS (ttm)0.12 Insider Own0.20% Shs Outstand516.40M Perf Week8.30%
Market Cap9.13B Forward P/E3.77 EPS next Y4.63 Insider Trans-1.10% Shs Float511.60M Perf Month8.40%
Income62.60M PEG56.65 EPS next Q1.00 Inst Own89.20% Short Float5.41% Perf Quarter7.31%
Sales11.62B P/S0.79 EPS this Y-95.00% Inst Trans2.01% Short Ratio3.58 Perf Half Y-6.92%
Book/sh21.81 P/B0.80 EPS next Y5.11% ROA0.20% Target Price22.07 Perf Year1.69%
Cash/sh1.23 P/C14.23 EPS next 5Y2.55% ROE0.50% 52W Range12.75 - 23.11 Perf YTD-13.03%
Dividend- P/FCF4.73 EPS past 5Y-58.00% ROI2.30% 52W High-24.36% Beta1.55
Dividend %- Quick Ratio0.80 Sales past 5Y8.30% Gross Margin40.00% 52W Low37.10% ATR0.73
Employees35000 Current Ratio1.30 Sales Q/Q5.00% Oper. Margin7.40% RSI (14)60.89 Volatility4.56% 4.34%
OptionableYes Debt/Eq1.12 EPS Q/Q182.90% Profit Margin0.50% Rel Volume0.59 Prev Close17.62
ShortableYes LT Debt/Eq0.99 EarningsMay 11 BMO Payout0.00% Avg Volume7.72M Price17.48
Recom2.40 SMA206.05% SMA5010.37% SMA200-5.30% Volume4,638,899 Change-0.79%
Jan-27-20Downgrade SVB Leerink Outperform → Mkt Perform $24
Jan-09-20Initiated Piper Sandler Neutral $21
Nov-07-19Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-05-19Downgrade CFRA Hold → Sell
Jul-19-19Initiated Wolfe Research Outperform
Jun-11-19Initiated Barclays Overweight $26
May-08-19Downgrade Wells Fargo Outperform → Market Perform $33 → $22
Mar-20-19Initiated SunTrust Buy $35
Mar-07-19Resumed UBS Neutral $31
Mar-06-19Upgrade Morgan Stanley Equal-Weight → Overweight $35
Feb-27-19Downgrade Bernstein Outperform → Mkt Perform $33
Jan-23-19Downgrade UBS Buy → Neutral
Nov-15-18Upgrade Argus Hold → Buy
Nov-06-18Upgrade BofA/Merrill Neutral → Buy
Oct-09-18Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-05-18Downgrade Mizuho Buy → Neutral
Aug-24-18Upgrade Evercore ISI In-line → Outperform
Aug-13-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Mar-15-18Reiterated Mizuho Buy $45 → $51
Jun-02-20 05:05PM  
03:31AM  
Jun-01-20 09:00AM  
08:30AM  
May-29-20 03:24PM  
11:32AM  
11:29AM  
May-22-20 09:13AM  
May-19-20 04:38PM  
May-18-20 11:52AM  
May-17-20 02:03PM  
May-14-20 10:08AM  
06:43AM  
May-13-20 12:23PM  
08:33AM  
07:40AM  
May-12-20 05:26PM  
04:16PM  
02:55PM  
11:50AM  
May-11-20 09:49PM  
05:30PM  
04:21PM  
01:00PM  
10:53AM  
10:09AM  
09:45AM  
09:32AM  
08:57AM  
08:50AM  
08:27AM  
08:15AM  
May-10-20 10:26AM  
07:33AM  
May-09-20 10:01PM  
May-08-20 08:59AM  
08:00AM  
May-07-20 01:57PM  
May-04-20 03:40PM  
01:06PM  
10:29AM  
May-01-20 02:45PM  
Apr-30-20 05:30PM  
Apr-28-20 07:00AM  
06:57AM  
Apr-24-20 10:49AM  
Apr-22-20 12:30PM  
Apr-21-20 01:47PM  
10:49AM  
Apr-17-20 12:10PM  
Apr-15-20 06:34PM  
06:29PM  
05:46PM  
05:00PM  
Apr-14-20 03:35PM  
01:35PM  
12:45PM  
Apr-08-20 01:42PM  
Apr-07-20 09:45AM  
Apr-05-20 10:22AM  
Apr-03-20 02:39AM  
02:36AM  
Apr-02-20 10:36AM  
Mar-31-20 08:57AM  
Mar-30-20 08:05AM  
Mar-29-20 11:49AM  
Mar-28-20 11:30AM  
Mar-27-20 06:45PM  
01:20PM  
09:30AM  
09:10AM  
Mar-26-20 08:23AM  
07:22AM  
07:01AM  
06:45AM  
06:45AM  
Mar-25-20 02:24PM  
01:48PM  
01:30PM  
11:20AM  
10:00AM  
Mar-24-20 09:57AM  
Mar-22-20 10:13AM  
Mar-21-20 11:03AM  
10:23AM  
Mar-20-20 09:51AM  
09:11AM  
08:56AM  
07:47AM  
07:44AM  
06:27AM  
Mar-19-20 04:50PM  
03:49PM  
03:25PM  
02:56PM  
Mar-17-20 01:41PM  
Mar-11-20 12:41PM  
10:00AM  
Mar-10-20 12:59PM  
08:00AM  
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Malik RajivPresidentMar 03Option Exercise0.0043,3830283,195Mar 04 06:41 PM
BRESCH HEATHER MChief Executive OfficerMar 03Option Exercise0.0070,4960302,999Mar 04 06:38 PM
Parks Kenneth ScottChief Financial OfficerMar 03Option Exercise0.0013,945039,476Mar 04 06:33 PM
Campbell PaulSee RemarksMar 03Option Exercise0.002200583Mar 04 06:32 PM
Campbell PaulSee RemarksMar 03Option Exercise0.002,906031,238Mar 04 06:32 PM
Mauro AnthonyChief Commercial OfficerMar 03Option Exercise0.0019,3670125,321Mar 04 06:31 PM
PARRISH MARK WDirectorMar 02Option Exercise0.006,011045,795Mar 04 06:48 PM
VANDERVEEN RANDALL LDirectorMar 02Option Exercise0.006,011050,217Mar 04 06:44 PM
Malik RajivPresidentMar 02Option Exercise0.0048,1610260,076Mar 04 06:41 PM
BRESCH HEATHER MChief Executive OfficerMar 02Option Exercise0.0073,2130264,089Mar 04 06:38 PM
van der Meer Mohr PaulineDirectorMar 02Option Exercise0.006,01108,695Mar 04 06:37 PM
Lyons Dillon JoEllenDirectorMar 02Option Exercise0.006,011018,039Mar 04 06:35 PM
MARK RICHARD ADirectorMar 02Option Exercise0.009,007013,007Mar 04 06:35 PM
KORMAN HARRYDirectorMar 02Option Exercise0.006,011028,945Mar 04 06:35 PM
Parks Kenneth ScottChief Financial OfficerMar 02Option Exercise0.0021,646034,082Mar 04 06:33 PM
Campbell PaulSee RemarksMar 02Option Exercise0.005510494Mar 04 06:32 PM
Campbell PaulSee RemarksMar 02Option Exercise0.006,109030,550Mar 04 06:32 PM
DIMICK NEIL FDirectorMar 02Option Exercise0.006,011053,017Mar 04 06:32 PM
Vollebregt Sjoerd SDirectorMar 02Option Exercise0.006,011048,269Mar 04 06:33 PM
HIGGINS MELINA EDirectorMar 02Option Exercise0.006,011039,131Mar 04 06:30 PM
Cindrich Robert JDirectorMar 02Option Exercise0.006,011027,479Mar 04 06:31 PM
Mauro AnthonyChief Commercial OfficerMar 02Option Exercise0.0021,6460115,119Mar 04 06:31 PM
Campbell PaulSee RemarksFeb 05Sale23.0011,611267,05325,413Feb 07 06:00 PM
HIGGINS MELINA EDirectorAug 15Buy17.6820,000353,54833,120Aug 19 07:29 PM
Vollebregt Sjoerd SDirectorAug 14Buy18.8124,000451,43942,258Aug 15 06:30 PM
Vollebregt Sjoerd SDirectorAug 13Buy19.1110,000191,10018,258Aug 15 06:30 PM
COURY ROBERT JDirectorAug 02Buy20.0649,8591,000,012947,194Aug 05 08:00 AM
MARK RICHARD ADirectorJul 31Buy20.974,00083,8744,000Aug 02 06:48 PM
COURY ROBERT JDirectorJun 24Option Exercise0.00750,00001,309,835Jun 25 08:04 PM